Ben Scruggs

Ben is a Principal at Hatteras Venture Partners, where he supports the firm’s overall operations, existing portfolio strategy, deal flow activities, and due diligence. Prior to joining Hatteras in 2016, Ben was a postdoctoral fellow in the Epigenetics and Stem Cell Biology Laboratory at the National Institute of Environmental Health Sciences. He has performed research in the fields of genomics, metabolism, RNA biology, and transcription regulation. Ben serves as a director on the board of IMMvention Therapeutix. He also serves as a board observer at Altis Biosystems, Dropworks, Myeloid Therapeutics, Qpex Biopharma, and Trefoil Therapeutics, and he was formerly a board observer at Graybug Vision (Nasdaq: GRAY). Ben received his B.E. in biomedical engineering from Vanderbilt University and a Ph.D. in molecular cell biology from Washington University in St. Louis.